Author:
Liu Shuaibing,Zhao Shiyu,Zhang XueXia,Chun Yong Chan Eric,Wang Ziteng,Li Hang,Tian Xin
Reference16 articles.
1. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma;Javle;J. Clin. Oncol.,2018
2. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma;Botrus;Expert Opin. Invest. Drugs,2021
3. A. UFD, FDA grants accelerated approval to infgratinib for metastatic cholangiocarcinoma, 2021.
4. Infigratinib: first approval;Kang;Drugs,2021
5. Q.T. I, TRUSELTIQ (infgratinib) Multi-Discipline Review Files, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214622Orig1s000MultidisciplineR.pdf.